Skip to main content
SpringerLink
Log in
Book cover

National Institute of Allergy and Infectious Diseases, NIH pp 385–396Cite as

A Model System for Studying Mechanisms of B-cell Transformation in Systemic Autoimmunity

  • Conference paper

  • 867 Accesses

Part of the book series: Infectious Disease ((ID))

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Sultan SM, Ioannou Y, Isenberg DA (2000) Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Rheumatology 39:1147–1152.

    Article  PubMed  CAS  Google Scholar 

  2. Cibere J, Sibley J, Haga M (2000) Systemic lupus erythematosus and the risk of malignancy. Lupus 10:394–400.

    Article  Google Scholar 

  3. Varoczy L, Gergely L, Zeher M, Szegedi G, Illes A (2002) Malignant lymphoma-asociated autoimmune diseases- a descriptive epidemiological study. Rheumatol Int 22:233–237.

    Article  PubMed  Google Scholar 

  4. Mackay I, Rose NR (2001) Autoimmunity and lymphoma: tribulations of B cells. Nature Immunol 2:793–795.

    Article  CAS  Google Scholar 

  5. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L (1998) Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 317:180–181.

    PubMed  CAS  Google Scholar 

  6. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH (1996) Rheumatoid arthritis and cancer risk. Eur J Cancer 32:1753–1757.

    Article  Google Scholar 

  7. Voulgarelis M, Moutsopoulos HM (2001) Malignant lymphoma in primary Sjogren's syndrome. Isr Med Assoc J 3:761–766.

    PubMed  CAS  Google Scholar 

  8. Hyjek E, Isaacson PG (1988) Primary B cell lymphoma of the thyroid and its relationship to Hashimoto's thyroiditis. Hum Pathol 19:1315–1326.

    Article  PubMed  CAS  Google Scholar 

  9. Zufferey P, Meyer OC, Grossin M, Kahn MF (1995) Primary Sjőgren's syndrome (SS) and malignant lymphoma. A retrospective cohort study of 55 patients with SS. Scand. J Rheumatol 24:342–345.

    CAS  Google Scholar 

  10. Burke JS (1999) Are there site-specific differences among the MALT lymphomas- morphologic, clinical? Am J Clin Pathol 111:S133–S143.

    PubMed  CAS  Google Scholar 

  11. Matsuzuka F, Miyauchi A, Katayama S, Narabayashi I, Ikeda H, Kuma K, Sugawara M (1993) Clinical aspects of primary thyroid lymphoma: diagnosis and treatment based on our experience of 119 cases. Thyroid 3:93–99.

    Article  PubMed  CAS  Google Scholar 

  12. Ferri C, Sebastiani M, Giuggioli D, Cazzato M, Longombardo G, Antonelli A, Puccini R, Michelassi C, Zignego AL (2004) Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 33:355–374.

    Article  PubMed  Google Scholar 

  13. Holm LE, Blomgren H, Lowhagen T (1985) Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med 312:601–604.

    Article  PubMed  CAS  Google Scholar 

  14. Kato I, Tajima K, Suchi T, Aozasa K, Matsuzuka F, Kuma K, Tom-inaga S (1985) Chronic thyroiditis as a risk factor of B-cell lym-phoma in the thyroid gland. Jpn J Cancer Res 76:1085–1090.

    PubMed  CAS  Google Scholar 

  15. Royer B, Cazals-Hatem D, Sibilia J, Agbalika F, Cayuela JM, Soussi T, Maloisel F, Clauvel JP, Brouet JC, Mariette X (1997) Lymphomas in patients with Sjőgren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and sites, nodal and are not associated with viruses. Blood 90:766–775.

    PubMed  CAS  Google Scholar 

  16. Straus SE, Jaffe ES, Puck JM, Dale JK, Elkon KB, Rosen-Wolff A, Peters AM, Sneller MC, Hallahan CW, Wang J, Fischer RE, Jackson CM, Lin AY, Baumler C, Siegert E, Marx A, Vaishnaw AK, Grodzicky T, Fleisher TA, Lenardo MJ (2001) The development of lymphomas in families with autoimmune lymphopro-liferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 98:194–200.

    Article  PubMed  CAS  Google Scholar 

  17. Sneller MC, Wang J, Dale JK, Strober W, Middelton LA, Choi Y, Fleisher TAM, Lim S, Jaffe ES, Puck JM, Lenardo MJ, Straus SE (1997) Clincial, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood 89:1341–1348.

    PubMed  CAS  Google Scholar 

  18. Davidson WF, Giese T, Fredrickson TN (1998) Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J Exp Med 187:1825–1838.

    Article  PubMed  CAS  Google Scholar 

  19. Landowski TH, Moscinski L, Burke R, Buyuksal I, Painter JS, Goldstein S, Dalton WS (2001) CD95 antigen mutations in hematopoietic malignancies. Leuk Lymphoma 42:835–846.

    Article  PubMed  CAS  Google Scholar 

  20. Wohlfart S, Sebinger D, Gruber P, Buch J, Polgar D, Krupitza G, Rosner M, Hengstschlager M, Raderer M, Chott A, Mul-lauer L (2004) FAS (CD95) mutations are rare in gastric MALT lymphoma but occur more frequently in primary gastric diffuse large B-cell lymphoma. Am J Pathol 164:1081–1089.

    Article  PubMed  CAS  Google Scholar 

  21. Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH (1997) Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 40:761–768.

    Article  PubMed  CAS  Google Scholar 

  22. Shin MS, Kim HS, Kang CS, Park WS, Kim SY, Lee SN, Lee JH, Park JY, Jang JJ, Kim CW, Kim SH, Lee JY, Yoo NJ, Lee SH (2002) Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. Blood 99:4094–4099.

    Article  PubMed  CAS  Google Scholar 

  23. De Re V, De Vita S, Marzotto A, Rupolo M, Gloghini A, Pivetta B, Gasparotto D, Carbone A, Boiocchi M (2000) Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia. Blood 96:3578–3584.

    PubMed  Google Scholar 

  24. Mariette X(2001) Lymphomas complicating Sjőgren's syndrome and hepatitis C virus infection may share a common pathogene-sis: chronic stimulation of rheumatoid factor B cells. Ann Rheum Dis 60:1007–1010.

    Article  PubMed  CAS  Google Scholar 

  25. Martin T, Weber C, Levallois H, Labouret N, Soley A, Koenig S, Korganow AS, Pasquali JL (2000) Salivary gland lymphomas in patients with Sjőgren's syndrome may frequently develop from rheumatoid factor B cells. Arthritis Rheum 43:908–916.

    Article  PubMed  CAS  Google Scholar 

  26. Eng MA, Kallemuchikkal U, Gorevic PD (2000) Hepatitis virus, C autoimmunity and lymphoproliferation. Mt Sinai J Med 67:120–132.

    PubMed  CAS  Google Scholar 

  27. Weng WK, Levy S (2003) Hepatitis C virus (HCV) and lym-phomagenesis. Leuk Lymphoma 44:1113–1120.

    Article  PubMed  CAS  Google Scholar 

  28. De Re V, De Vita S, Gasparotto D, Marzotto A, Carbone A, Fer-raccioli G, Boiocchi M (2002) Salivary gland B cell lymphop-roliferative disorders in Sjőgren's syndrome present a restricted use of antigen receptor gene segments similar to those used by hepatitis C virus-associated non-Hodgkins's lymphomas. Eur J Immunol 32:903–910.

    Article  PubMed  Google Scholar 

  29. Isaacson PG (1999) Mucosa-associated lymphoid tissue lym-phoma. Semin Hematol 36:139–147.

    PubMed  CAS  Google Scholar 

  30. Crump M, Gospodarowicz M, Shepherd FA (1999) Lymphoma of the gastrointestinal tract. Semin Oncol 26:324–337.

    PubMed  CAS  Google Scholar 

  31. De Re V, De Vita S, Marzotto A, Gloghini A, Pivetta B, Gasparotto D, Cannizzaro R, Carbone A, Boiocchi M (2000) Pre-malignant and malignant lymphoproliferations in an HCV-infected type II mixed cryoglobulinemic patient are sequential phases of an antigen-driven pathological process. Int J Cancer 87:211–216.

    Article  PubMed  Google Scholar 

  32. Lossos IS, Alizadeh AA, Eisen MB, Chan WC, Brown PO, Bot-stein D, Staudt LM, Levy R (2000) Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci USA 97:10,209–10,213.

    Article  CAS  Google Scholar 

  33. Bahler DW, Levy R (1992) Clonal evolution of a follicular lym-phoma: evidence for antigen selection. Proc Natl Acad Sci USA 89:6770–6774.

    Article  PubMed  CAS  Google Scholar 

  34. Matolcsy A, Schattner EJ, Knowles DM, Casali P (1999) Clonal evolution of B cells in transformation from low- to high-grade lymphoma. Eur J Immunol 29:1253–1264.

    Article  PubMed  CAS  Google Scholar 

  35. Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C, Moine P, Rossi J, Klein B, Tarte K (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103:3148–3157.

    Article  PubMed  CAS  Google Scholar 

  36. He B, Chadburn A, Jou E, Schattner EJ, Knowles DM, Cerutti A (2004) Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 172:3268–3279.

    PubMed  CAS  Google Scholar 

  37. Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kinds-vogel W, Gross JA, Greipp PR, Jelinek DF (2004) Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103:689–694.

    Article  PubMed  CAS  Google Scholar 

  38. Masood R, Zhang M, Bond W, Scadden DT, Moudgil T, Law RE, Kaplan MH, Jung B, Espina BM, Lunardi-Iskandar Y (1995) Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood 85:3423–3430.

    PubMed  CAS  Google Scholar 

  39. Lu ZY, Zhang XG, Rodriguez C, Wijdenes J, Gu ZJ, Morel-Fournier B, Harousseau JL, Bataille R, Rossi JF, Klein B (1995) Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. Blood 85:2521–2527.

    PubMed  CAS  Google Scholar 

  40. Groux H, Cottrez F (2003) The complex role of interleukin-10 in autoimmunity. J Autoimmun 20:281–285.

    Article  PubMed  CAS  Google Scholar 

  41. Lopatin U, Yao X, Williams RK, Bleesing JJ, Dale JK, Wong D, Teruya-Feldstein J, Fritz S, Morrow MR, Fuss I, Sneller MC, Raffeld M, Fleisher TA, Puck JM, Strober W, Jaffe ES, Straus SE (2001) Increases in circulating and lymphoid tissue inter-leukin-10 in autoimmune lymphoproliferative syndrome are associated with disease expression. Blood 97:3161–3170.

    Article  PubMed  CAS  Google Scholar 

  42. Kalled S (2005) The role of BAFF in immune function and implications for autoimmunity. Immunol Rev 204:43–54.

    Article  PubMed  CAS  Google Scholar 

  43. Ng LG, Mackay CR, Mackay F (2005) The BAFF/APRIL system: life beyond B cells. Mol Immunol 42:763–772.

    Article  PubMed  CAS  Google Scholar 

  44. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683–765.

    Article  PubMed  CAS  Google Scholar 

  45. Mocellin S, Marincola F, Rossi C, Nitti D, Lise M (2004) The multi-faceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev 15:61–67.

    Article  PubMed  CAS  Google Scholar 

  46. Cush JJ, Splawski J, Thomas BR, McFarlin JE, Schulze-Koops H, Davis LS, Fujita K, Lipsky PE (1995) Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum 38:96–104.

    Article  PubMed  CAS  Google Scholar 

  47. Perrier S, Serre AF, Dubost JJ, Beaujon G, Plazonnet MP, Albuis-son E, Sauvezie B (2000) Increased serum levels of interleukin 10 in Sjogren's syndrome; correlation with increased IgG1. J Rheumatol 27:935–939.

    PubMed  CAS  Google Scholar 

  48. Beebe AM, Cua DJ, de Waal Malefyt R (2002) The role of inter-leukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Cytokine Growth Factor Rev 13:403–412.

    Article  PubMed  CAS  Google Scholar 

  49. Ramachandra S, Metcalf RA, Frederickson T, Marti GE, Raveche E (1996) Requirement for increased IL-10 in the development of B-1 lymphoproliferative disease in a murine model of CLL. J Clin Invest 98:1788–1793.

    Article  PubMed  CAS  Google Scholar 

  50. Czarneski J, Lin YC, Chong S, McCarthy B, Fernandes H, Parker G, Mansour A, Huppi K, Marti GE, Raveche E (2004) Studies in NZB IL-10 knockout mice of the requirement of IL-10 for progression of B-cell lymphoma. Leukemia 18:597– 606.

    Article  PubMed  CAS  Google Scholar 

  51. Mackay F, Kalled SL (2002) TNF ligands and receptors in auto-immunity: an update. Curr Opin Immunol 14:783–790.

    Article  PubMed  CAS  Google Scholar 

  52. Mackay F, Schneider P, Rennert P, Browning J (2003) BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 21:231–264.

    Article  PubMed  CAS  Google Scholar 

  53. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL (1999) Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190:1697–1710.

    Article  PubMed  CAS  Google Scholar 

  54. Khare SD, Sarosi I, Xia XZ, McCabe S, Miner K, Solovyev I, Hawkins N, Kelley M, Chang D, Van G, Ross L, Delaney J, Wang L, Lacey D, Boyle WJ, Hsu H (2000) Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 97:3370–3375.

    Article  PubMed  CAS  Google Scholar 

  55. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, Xu W, Parrish-Novak J, Foster D, Lofton-Day C, Moore M, Lit-tau A, Grossman A, Haugen H, Foley K, Blumberg H, Harrison K, Kindsvogel W, Clegg CH (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404:949–950.

    Article  Google Scholar 

  56. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, Tschopp J, Cachero TG, Batten M, Wheway J, Mauri D, Cav-ill D, Gordon TP, Mackay CR, Mackay F (2002) Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 109:59–68.

    PubMed  CAS  Google Scholar 

  57. Cheema GS, Roschke V, Hilbert DM, Stohl W (2001) Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44:1313–1319.

    Article  PubMed  CAS  Google Scholar 

  58. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ, Bastian H, Kimberly RP, Zhou T (2001) Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166:6–10.

    PubMed  CAS  Google Scholar 

  59. Zhang HG, Yang P, Xie J, Liu Z, Liu D, Xiu L, Zhou T, W a n g Y, Hsu HC, Mountz JD (2002) Depletion of collagen II-reactive T cells and blocking of B cell activation prevents collagen II-induced arthritis in DBA/1j mice. J Immunol 168:4164–4172.

    PubMed  CAS  Google Scholar 

  60. Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, Rixon M, Schou O, Foley KP, Haugen H, McMillen S, Waggie K, Schreckhise RW, Shoemaker K, Vu T, Moore M, Grossman A, Clegg CH (2001) TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease impaired B cell maturation in mice lacking BLyS. Immunity 15:289–302.

    Article  PubMed  CAS  Google Scholar 

  61. Chui A, Xu W, He B, Dillon SR, Gross J, Sievers E, Qiao X, Santini P, Hyjek E, Lee J-W, Cesarman E, Chadburn A, Knowles DM, Cerutti A (2006) Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood.

    Google Scholar 

  62. Endo T, Nishio M, Enzler T, Cottam HB, Fukada T, James DF, Karin M, Kipps TJ (2006) BAFF and April support chronic lymphocytic leukemia B cell survival through activation of the canonical NF-κB pathway. Blood.

    Google Scholar 

  63. Eisenberg R (2003) Mechanisms of Autoimmunity. Immunol Res 27:203–218.

    Article  PubMed  CAS  Google Scholar 

  64. Zhang JQ, Okumura C, McCarty T, Shin MS, Mukhopadhyay P, Hori M, Torrey TA, Naghashfar Z, Zhou JX, Lee CH, Roopenian DC, Morse HC 3rd Davidson WF (2004) Evidence for selective transformation of autoreactive immature plasma cells in mice deficient in Fasl. J Exp Med 200:1467–1478.

    Article  PubMed  CAS  Google Scholar 

  65. Peng SL, Robert ME, Hayday AC, Craft J (1996) A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice. J Exp Med 184:1149–1154.

    Article  PubMed  CAS  Google Scholar 

  66. Schmidt SM, Schag K, Muller MR, Weck MM, Appel S, Kanz L, Grunebach F, Brossart P (2003) Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 102:571–576.

    Article  PubMed  CAS  Google Scholar 

  67. Murray PG, Flavell JR, Baumforth KR, Toomey SM, Lowe D, Crocker J, Ambinder RF, Young LS (2001) Expression of the tumour necrosis factor receptor-associated factors 1 and 2 in Hodgkin's disease. J Pathol 194:158–164.

    Article  PubMed  CAS  Google Scholar 

  68. Kari L, Loboda A, Nebozhyn M, Rook AH, Vonderheid EC, Nichols C, Virok D, Chang C, Hornig WH, Johnston J, Wysocka M, Showe LC (2002) Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med 197:1477–1488.

    Article  Google Scholar 

  69. Garcia V, Garcia JM, Pena C, Silva J, Dominguez G, Rodriguez R, Maximiano C, Espinosa R, Espana P, Bonilla F (2005) The GADD45, ZBRK1 and BRCA1 pathway: quantitative analysis of mRNA expression in colon carcinomas. J Pathol 206:92–99.

    Article  PubMed  CAS  Google Scholar 

  70. Besset V, Rhee K, Wolgemuth DJ (1998) The identification and characterization of expression of Pftaire-1, a novel Cdk member, family suggest its function in the mouse testis and nervous system. Mol Reprod Dev 50:18–29.

    Article  PubMed  CAS  Google Scholar 

  71. Davies FE, Dring AM, Li C, Rawstron AC, Shammas MA, O'Connor SM, Fenton JA, Hideshima T, Chauhan D, Tai IT, Robinson E, Auclair D, Rees K, Gonzalez D, Ashcroft AJ, Das-gupta R, Mitsiades N, Chen LB, Wong LB, Munshi NC, Morgan GJ, Anderson KC (2003) Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 102:4504–4511.

    Article  PubMed  CAS  Google Scholar 

  72. Muzio G, Canuto RA, Trombetta A, Maggiora M (2001) Inhibition of cytosolic class 3 aldehyde dehydrogenase by antisense oligonucleotides in rat hepatoma cells. Chem Biol Interact 130– 132, 219–225.

    Google Scholar 

  73. Sladek NE, Kollander R, Sreerama L, Kiang DT (2002) Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemothera-peutic regimens. Cancer Chemother Pharmacol 49:309–321.

    Article  PubMed  CAS  Google Scholar 

  74. Guehenneux F, Duret L, Callanan MB, Bouhas R, Hayette R, Berthet C, Samarut C, Rimokh R, Birot AM, Wang Q, Magaud JP, Rouault JP (1997) Cloning of the mouse BTG3 gene and definition of a new gene family (the BTG family) involved in the negative control of the cell cycle. Leukemia 11:370–375.

    Article  PubMed  CAS  Google Scholar 

  75. Ge K, Duhadaway J, Sakamuro D, Wechsler-Reya R, Reynolds C, Prendergast GC (2000) Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity. Int J Cancer 85:376–383.

    Article  PubMed  CAS  Google Scholar 

  76. Wang X, Wang L, Callister MD, Putnam JB, Mao L, Li L (2001) Human Rad17 is phosphorylated upon DNA damage and also overexpressed in primary non-small cell lung cancer tissues. Cancer Res 61:7417–7421.

    PubMed  CAS  Google Scholar 

  77. Enlund F, Persson F, Stenman G (2004) Molecular analyses of the candidate tumor gene, suppressor PLAGL1, in benign and malignant salivary gland tumors. Eur J Oral Sci 112:545–547.

    Article  PubMed  CAS  Google Scholar 

  78. Tsukasaki K, Miller CW, Greenspun E, Eshaghian S, Kawabata H, Fujimoto T, Tomonaga M, Sawyers C, Said JW, Koeffler HP (2001) Mutations in the mitotic check gene, point MAD1L1, in human cancers. Oncogene 20:3301–3305.

    Article  PubMed  CAS  Google Scholar 

  79. Reap EA, Piecyk ML, Oliver A, Sobel ES, Waldschmidt T, Cohen PL, Eisenberg RA (1996) Phenotypic abnormalities of splenic and bone marrow B cells in lpr and gld mice. Clin Immunol 78:21–29.

    CAS  Google Scholar 

  80. Mandik-Nayak L, Seo SJ, Sokol C, Potts KM, Bui A, Erikson J (1999) MRL-lpr/lpr mice exhibit a defect in maintaining developmental arrest and follicular exclusion of anti-double-stranded DNA B cells. J Exp Med 189:1799–1814.

    Article  PubMed  CAS  Google Scholar 

  81. De Vita S, Boiocchi M, Sorrentino D, Carbone A, Avellini C, Dolcetti R, Marzotto A, Gloghini A, Bartoli E, Beltrami CA, Fer-raccioli G (1997) Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjogren's syndrome. Arthritis Rheum 40:318–331.

    Article  PubMed  Google Scholar 

  82. Monteverde A, Ballare M, Pileri S (1997) Hepatic lymphoid aggregates in chronic hepatitis C and mixed cryoglobulinemia. Springer Semin Immunopathol 19:99–110.

    Article  PubMed  CAS  Google Scholar 

  83. Marquart HV, Svendsen A, Rasmussen JM, Nielsen CH, Junker P, Svehag SE, Leslie RG (1995) Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosis. Clin Exp Immunol 101:60–65.

    Article  PubMed  CAS  Google Scholar 

  84. Wilson JG, Ratnoff WD, Schur PH, Fearon DT (1986) Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on neutrophils of patients with systemic lupus erythematosis. Arthritis Rheum 29:739–747.

    Article  PubMed  CAS  Google Scholar 

  85. Schwab J, Illges H (2001) Silencing of CD21 expression in syno-vial lymphocytes is dependent on methylation of the CD21 promoter CpG island. Rheumatol Int 20:133–137.

    Article  PubMed  CAS  Google Scholar 

  86. Illges H, Braun M, Peter HH, Melchers I (2000) Reduced expression of the complement receptor type 2 (CR2,CD21) by synovial fluid B and T lymphocytes. Clin Exp Immunol 122:270–276.

    Article  PubMed  CAS  Google Scholar 

  87. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE (2005) Identification and characterization of circulating human transitional B cells. Blood 105:4390–4398.

    Article  PubMed  CAS  Google Scholar 

  88. Wehr C, Eibel H, Masilamani M, Illges H, Schlesier M, Peter HH, Warnatz K (2004) A new CD21low B cell population in the peripheral blood of patients with SLE. Clin Immunol 113:161–171.

    Article  PubMed  CAS  Google Scholar 

  89. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ (2004) CD40/ CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 22:307–328.

    Article  PubMed  CAS  Google Scholar 

  90. Grammer AC, Lipsky PE (2002) CD154-CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosis. Arthritis Rheum 46:1417–1429.

    Article  PubMed  CAS  Google Scholar 

  91. Yin Z, Bahtiyar G, Zhang N, Liu L, Zhu P, Robert ME, McNiff J, Madaio MP, Craft J (2002) IL-10 regulates murine lupus. J Immunol 169:2148–2155.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Marlene and Stewart Greenebaum Cancer Center and Department of Microbiology and Immunology, and the Center for Vascular and Inflammatory Diseases, BioPark Building 1, University of Maryland, Baltimore, MD, USA

    Wendy F. Davidson

  2. Marlene and Stewart Greenebaum Cancer Center and Center for Vascular and Inflammatory Diseases, University of Maryland, Baltimore, MD, USA

    Partha Mukhopadhyay

  3. Department of Microbiology and Immunology, University of Maryland School of Medicine, and Center for Vascular and Inflammatory Diseases, University of Maryland, Baltimore, MD, USA

    Mark S. Williams

  4. Laboratory of Immunopathology, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rockville, MD, USA

    Zohreh Naghashfar, Jeff X. Zhou & Herbert C. Morse III

Authors
  1. Wendy F. Davidson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Partha Mukhopadhyay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark S. Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zohreh Naghashfar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jeff X. Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Herbert C. Morse III
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Vassil St. Georgiev PhD Karl A. Western MD John J. McGowan PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this paper

Cite this paper

Davidson, W.F., Mukhopadhyay, P., Williams, M.S., Naghashfar, Z., Zhou, J.X., Morse, H.C. (2008). A Model System for Studying Mechanisms of B-cell Transformation in Systemic Autoimmunity. In: Georgiev, V.S., Western, K.A., McGowan, J.J. (eds) National Institute of Allergy and Infectious Diseases, NIH. Infectious Disease. Humana Press. https://doi.org/10.1007/978-1-59745-569-5_43

Download citation

Publish with us

Policies and ethics

Search

Navigation